8-K Announcements
6Material company update
Nov 13, 2025·SEC
Material company update
Nov 10, 2025·SEC
Material company update
Nov 6, 2025·SEC
Metsera, Inc.(MTSR)Earnings, Financials & Key Ratios
MTSR•NASDAQ
$70.50
$7.43B mkt cap·Price updated Apr 24, 2026
AboutMetsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$225M-414.8%
- Net Income-$209M-343.0%
- EPS (Diluted)-2.03-113.7%
- ROE-108.4%-126.2%
- Debt/Equity0.03
- Interest Coverage-1008.22
MTSR Key Insights
Metsera, Inc. (MTSR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 92 (top 8%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 25.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MTSR Price & Volume
Metsera, Inc. (MTSR) stock price & volume — 10-year historical chart
Loading chart...
MTSR Growth Metrics
Metsera, Inc. (MTSR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-56.92%
5 Years-56.92%
3 Years-56.92%
Last Year-84.47%
MTSR Recent Earnings
Metsera, Inc. (MTSR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/4 qtrs (0%)
Q4 2025Latest
Nov 12, 2025EPS
$1.11
Est $0.56
-98.2%
Revenue
—
Q3 2025
Jul 28, 2025EPS
$0.66
Est $0.66
-0.3%
Revenue
—
Q2 2025
May 12, 2025EPS
$1.03
Est $0.85
-21.2%
Revenue
—
Q2 2025
Mar 26, 2025EPS
$3.52
Est $0.80
-340.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $1.11vs $0.56-98.2% | — |
| Q3 2025 | Jul 28, 2025 | $0.66vs $0.66-0.3% | — |
| Q2 2025 | May 12, 2025 | $1.03vs $0.85-21.2% | — |
| Q2 2025 | Mar 26, 2025 | $3.52vs $0.80-340.0% | — |
Based on last 4 quarters of dataView full earnings history →
MTSR Peer Comparison
Metsera, Inc. (MTSR) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 TERN | 4.64B | 52.97 | -47.29 | -29.95% | 0.00 | |||
 GPCR | 2.35B | 40.84 | -17.02 | -14.55% | 0.00 | |||
 PEPG | 127.07M | 1.85 | -0.87 | -75.73% | 0.12 | |||
 NVO | 203.36B | 45.76 | 12.65 | 6.43% | 33.14% | 61.1% | 0.67 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 178.7B | 331.11 | 23.27 | 9.92% | 20.95% | 89.41% | 6.31 | |
 RYTM | 6.6B | 96.61 | -31.06 | 45.83% | -93.84% | -204.35% | 1.77 |
Compare MTSR vs Peers
Metsera, Inc. (MTSR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MTSR Income Statement
Metsera, Inc. (MTSR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 43.67M | 224.83M | 337.51M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 15.04M | 26.8M | 44.86M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 15.56M | 107.52M | 220.3M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 13.06M | 90.52M | 2.13M |
| Operating Income | -43.67M▲ 0% | -224.83M▼ 414.9% | -337.51M▲ 0% |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -414.86% | - |
| EBITDA | -43.67M | -224.82M | -337.48M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -414.85% | - |
| D&A (Non-Cash Add-back) | 2K | 14K | 35K |
| EBIT | -47.21M | -218.24M | -393.97M |
| Net Interest Income | 1.92M | 5.96M | 17.83M |
| Interest Income | 1.92M | 6.18M | 17.98M |
| Interest Expense | 0 | 223K | 152K |
| Other Income/Expense | -3.54M | 6.37M | 14.71M |
| Pretax Income | -47.21M▲ 0% | -218.47M▼ 362.8% | -322.81M▲ 0% |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | -9.34M | -8.4M |
| Effective Tax Rate % | 0% | 4.27% | 2.6% |
| Net Income | -47.21M▲ 0% | -209.13M▼ 343.0% | -314.41M▲ 0% |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -343.01% | - |
| Net Income (Continuing) | -47.21M | -209.13M | -314.41M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -0.95▲ 0% | -2.03▼ 113.7% | -2.99▲ 0% |
| EPS Growth % | - | -113.68% | - |
| EPS (Basic) | -0.95 | -2.03 | - |
| Diluted Shares Outstanding | 49.94M | 103.04M | 105.03M |
| Basic Shares Outstanding | 49.94M | 103.04M | 105.03M |
| Dividend Payout Ratio | - | - | - |
MTSR Balance Sheet
Metsera, Inc. (MTSR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
| Total Current Assets | 76.8M | 359.13M | 461.41M |
| Cash & Short-Term Investments | 75.19M | 352.45M | 448.46M |
| Cash Only | 75.19M | 352.45M | 448.46M |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 761K | 4.63M | 2.29M |
| Total Non-Current Assets | 92.04M | 91.86M | 106.23M |
| Property, Plant & Equipment | 27K | 1.44M | 641K |
| Fixed Asset Turnover | - | - | 0.00x |
| Goodwill | 22.18M | 21.89M | 23.4M |
| Intangible Assets | 69.42M | 68.52M | 73.25M |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 410K | 0 | 12.06M |
| Total Assets | 168.84M▲ 0% | 450.99M▲ 167.1% | 567.64M▲ 0% |
| Asset Turnover | - | - | 0.00x |
| Asset Growth % | - | 167.11% | 97.6% |
| Total Current Liabilities | 20.17M | 67.31M | 108.49M |
| Accounts Payable | 2.66M | 20.84M | 20.23M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 0 | 8.39M | 2.41M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 14.86M | 25.32M | 56.59M |
| Current Ratio | 3.81x | 5.34x | 5.34x |
| Quick Ratio | 3.81x | 5.34x | 5.34x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 50.17M | 96.33M | 121.96M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 701K | 1.6M |
| Deferred Tax Liabilities | 17.67M | 7.78M | 32.6M |
| Other Non-Current Liabilities | 32.5M | 87.85M | 366.77M |
| Total Liabilities | 70.34M | 163.64M | 230.45M |
| Total Debt | 0 | 9.8M | 2.84M |
| Net Debt | -75.19M | -342.64M | -445.62M |
| Debt / Equity | - | 0.03x | 0.03x |
| Debt / EBITDA | - | - | -0.01x |
| Net Debt / EBITDA | - | - | 1.32x |
| Interest Coverage | - | -1008.22x | -2591.91x |
| Total Equity | 98.5M▲ 0% | 287.35M▲ 191.7% | 337.19M▲ 0% |
| Equity Growth % | - | 191.72% | 159.8% |
| Book Value per Share | 1.97 | 2.79 | 3.21 |
| Total Shareholders' Equity | 98.5M | 287.35M | 337.19M |
| Common Stock | 0 | 0 | 1K |
| Retained Earnings | -48.02M | -257.15M | -518.68M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 2.75M | 1.16M | 10.55M |
| Minority Interest | 0 | 0 | 0 |
MTSR Cash Flow Statement
Metsera, Inc. (MTSR) cash flow — operating, investing & free cash flow history
| Line item | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
| Cash from Operations | -35.39M | -99.79M | -99.79M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | -181.94% | -188.76% |
| Net Income | -47.21M | -209.13M | -314.41M |
| Depreciation & Amortization | 2K | 14K | 35K |
| Stock-Based Compensation | 85K | 0 | 7.84M |
| Deferred Taxes | 0 | -9.34M | 0 |
| Other Non-Cash Items | 7.7M | 92.92M | 59.98M |
| Working Capital Changes | 4.02M | 25.75M | 15.16M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 2.6M | 16.55M | 8.73M |
| Cash from Investing | -28.24M | -43K | -199K |
| Capital Expenditures | -29K | -43K | -199K |
| CapEx % of Revenue | - | - | - |
| Acquisitions | -28.21M | 0 | 0 |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 123.68M | 377.95M | 489.63M |
| Debt Issued (Net) | 0 | -252K | -125K |
| Equity Issued (Net) | 1000K | 1000K | 2.33M |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 |
| Other Financing | -217K | -18.98M | -14.11M |
| Net Change in Cash | 60.22M▲ 0% | 277.25M▲ 360.4% | 260.87M▲ 0% |
| Free Cash Flow | -35.42M▲ 0% | -99.83M▼ 181.8% | -231.59M▲ 0% |
| FCF Margin % | - | - | - |
| FCF Growth % | - | -181.83% | - |
| FCF per Share | -0.71 | -0.97 | -0.97 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.48x | 0.74x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
MTSR Key Ratios
Metsera, Inc. (MTSR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2024 | TTM |
|---|---|---|
| Return on Equity (ROE) | -108.4% | -93.24% |
| Return on Invested Capital (ROIC) | - | 318.84% |
| Debt / Equity | 0.03x | 0.03x |
| Interest Coverage | -1008.22x | -2591.91x |
| FCF Conversion | 0.48x | 0.74x |
MTSR SEC Filings & Documents
Metsera, Inc. (MTSR) SEC filings — annual & quarterly reports (10-K, 10-Q)
MTSR Frequently Asked Questions
Metsera, Inc. (MTSR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Metsera, Inc. (MTSR) grew revenue by 0.0% over the past year. Growth has been modest.
Metsera, Inc. (MTSR) reported a net loss of $314.4M for fiscal year 2024.
Dividend & Returns
Metsera, Inc. (MTSR) has a return on equity (ROE) of -108.4%. Negative ROE indicates the company is unprofitable.
Metsera, Inc. (MTSR) had negative free cash flow of $231.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More MTSR
Metsera, Inc. (MTSR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates